Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
V.NRX Promising Preclinical Results in Restoring Vision After Optic Nerve Damage (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bluejay Diagnostics Inc BJDX

Healthcare Biotechnology

Recent & Breaking News (NDAQ:BJDX)

Bluejay Diagnostics Announces Reverse Stock Split

GlobeNewswire November 13, 2024

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

GlobeNewswire June 28, 2024

Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering

GlobeNewswire June 27, 2024

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

GlobeNewswire June 26, 2024

Bluejay Diagnostics Announces Reverse Stock Split

GlobeNewswire June 17, 2024

Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

GlobeNewswire January 2, 2024

Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

GlobeNewswire December 28, 2023

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

GlobeNewswire December 27, 2023

Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

GlobeNewswire November 9, 2023

Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

GlobeNewswire August 25, 2023

Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results

GlobeNewswire August 16, 2023

Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire August 10, 2023

Bluejay Diagnostics Announces Reverse Stock Split

GlobeNewswire July 21, 2023

Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy

GlobeNewswire May 19, 2023

Bluejay Diagnostics Reports First Quarter 2023 Financial Results

GlobeNewswire May 10, 2023

Bluejay Diagnostics Reports 2022 Financial Results

GlobeNewswire March 20, 2023

Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America

GlobeNewswire February 16, 2023

Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

GlobeNewswire November 9, 2022

Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire August 30, 2022

Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure

GlobeNewswire August 16, 2022